Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Ragini Kudchakar"'
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
(A) Average body weight of mice treated with each BRAF inhibitor in the experiment depicted in Figure 1C; (B) Encorafenib plasma exposure in mice following the last dose from the experiment depicted in Figure 1C. To estimate daily exposure on the BID
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e582a2e6528fa79c1c59d17f45ea091
https://doi.org/10.1158/1078-0432.22467995
https://doi.org/10.1158/1078-0432.22467995
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Purpose: Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis. We evaluated encorafenib in a phase I study in patients with BRAFi treatment-naïve and pretreated BRA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d33fd78b0f824a6d521ad7699f44e3c
https://doi.org/10.1158/1078-0432.c.6526808
https://doi.org/10.1158/1078-0432.c.6526808
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Biochemical and cellular potency of encorafenib, dabrafenib, and vemurafenib in biochemical and cell-based assays. Purified BRAF V600E kinase domain was used in the biochemical experiments, using kinase-dead MEK1 as a substrate and a phosphorylated M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e51957f9f54ec77b6c8a756ef60a095
https://doi.org/10.1158/1078-0432.22467989
https://doi.org/10.1158/1078-0432.22467989
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Dose-limiting toxicities occurring during cycle 1 in the dose-determining set by dose group, listed per patient.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aca8ca8218081401f1cec59089b4fcc7
https://doi.org/10.1158/1078-0432.22467983
https://doi.org/10.1158/1078-0432.22467983
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Proliferation half maximal inhibitory concentration (IC50) of encorafenib, dabrafenib, and vemurafenib against a panel of BRAF V600-mutant melanoma and colorectal cell lines. Red squares represent BRAF V600E-mutant, and blue squares represent BRAF V6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68828b4950b2f035b05cd735fbbd2b83
https://doi.org/10.1158/1078-0432.22467998.v1
https://doi.org/10.1158/1078-0432.22467998.v1
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Summary of pharmacokinetic parameters (cycle 1 day 1 [C1D1] and cycle 1 day 15 [C1D15]) by treatment group in the dose-escalation phase (QD regimen)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57bd14d32e67c38151e12bf226c3b67b
https://doi.org/10.1158/1078-0432.22467980
https://doi.org/10.1158/1078-0432.22467980
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Best percentage change in sum of longest diameters in target lesion from baseline, by patient, treatment group, and mutation status, in patients with BRAFi-naive (A) and pretreated (B) melanoma. Grouped analysis of patients in the dose-escalation and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0231a102b44c91f9710a9d7e67105389
https://doi.org/10.1158/1078-0432.22467992
https://doi.org/10.1158/1078-0432.22467992
Autor:
Marta Nyakas, Grant A. McArthur, Giordano Caponigro, Daniela Michel, Ana Arance, Amit Mahipal, Tim Demuth, Ragini Kudchakar, Vassilios Aslanis, Caroline Robert, Matteo S. Carlino, Yasuhide Yamada, Richard F. Kefford, Manuel Hidalgo, Carlos Gomez-Roca, Ryan J. Sullivan, Abdelkader Seroutou, Laure Moutouh-de Parseval, Darrin Stuart, Jean Pierre Delord, Reinhard Dummer
Publikováno v:
Clinical Cancer Research. 23:5339-5348
Purpose: Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis. We evaluated encorafenib in a phase I study in patients with BRAFi treatment-naïve and pretreated BRA
Autor:
Jean-Pierre, Delord, Caroline, Robert, Marta, Nyakas, Grant A, McArthur, Ragini, Kudchakar, Amit, Mahipal, Yasuhide, Yamada, Ryan, Sullivan, Ana, Arance, Richard F, Kefford, Matteo S, Carlino, Manuel, Hidalgo, Carlos, Gomez-Roca, Daniela, Michel, Abdelkader, Seroutou, Vassilios, Aslanis, Giordano, Caponigro, Darrin D, Stuart, Laure, Moutouh-de Parseval, Tim, Demuth, Reinhard, Dummer
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(18)